版本:
中国

BRIEF-Lipocine validates “no titration” dosing regimen with positive topline efficacy results for LPCN 1021

June 19 Lipocine Inc:

* Lipocine validates “no titration” dosing regimen with positive topline efficacy results for lpcn 1021, oral testosterone candidate

* Lipocine Inc- LPCN 1021 achieved primary endpoints confirming efficacy of twice daily oral administration

* Lipocine Inc- LPCN 1021 generally met pre-specified per dose secondary endpoints for twice daily oral administration

* Lipocine Inc- new drug application resubmission planned in Q3 of 2017

* Lipocine Inc - all drug related adverse events ("AES") were either mild or moderate in intensity and none were severe Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐